Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 254 entries
View as:

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00044577 Org: User:
Start: 07/16/02 End: 05/25/04 Due: 05/25/05

Drug Interaction Study Between Dolutegravir and Prednisone

Phase: N/A Priority: Normal
NCT ID: NCT01425099 Org: User:
Start: 09/30/11 End: 10/31/11 Due: 10/31/12

Evaluation of the Bioequivalence of a Combined Formulated Tablet

Phase: N/A Priority: Normal
NCT ID: NCT01622790 Org: User:
Start: 06/30/12 End: 08/31/12 Due: 08/31/13

Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT04425902 Org: User:
Start: 12/16/20 End: 03/10/21 Due: 03/10/22

HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults

Phase: N/A Priority: Normal
NCT ID: NCT00450580 Org: User:
Start: 03/31/07 End: 08/31/08 Due: 08/31/09

Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT00441688 Org: User:
Start: 03/15/07 End: 06/01/07 Due: 06/01/08

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

Phase: N/A Priority: Normal
NCT ID: NCT02415595 Org: User:
Start: 05/12/15 End: 08/21/17 Due: 08/21/18

Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection

Phase: N/A Priority: Normal
NCT ID: NCT02178592 Org: User:
Start: 01/23/15 End: 03/06/20 Due: 03/06/21

A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02354950 Org: User:
Start: 06/22/15 End: 09/16/16 Due: 09/16/17

A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults

Phase: N/A Priority: Normal
NCT ID: NCT00242879 Org: User:
Start: 08/31/05 End: 06/30/07 Due: 06/30/08

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT00827112 Org: User:
Start: 03/31/09 End: 07/31/11 Due: 07/31/12

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

Phase: N/A Priority: Normal
NCT ID: NCT01209117 Org: User:
Start: 09/30/10 End: 01/31/11 Due: 01/31/12

PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)

Phase: N/A Priority: Normal
NCT ID: NCT03327740 Org: User:
Start: 09/30/14 End: 12/31/19 Due: 12/31/20

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02373930 Org: User:
Start: 02/28/15 End: 09/30/15 Due: 09/30/16

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01290211 Org: User:
Start: 04/30/11 End: 06/30/11 Due: 06/30/12

Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay

Phase: N/A Priority: Normal
NCT ID: NCT00496782 Org: User:
Start: 07/31/07 End: 10/31/08 Due: 10/31/09

GW873140 In Combination With Combivir In HIV Infected Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00104429 Org: User:
Start: 01/31/05 End: 01/31/06 Due: 01/31/07

A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV

Phase: N/A Priority: Normal
NCT ID: NCT06970223 Org: User:
Start: 04/22/25 End: 07/07/26 Due: 07/07/27

Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin

Phase: N/A Priority: Normal
NCT ID: NCT04563845 Org: User:
Start: 11/09/20 End: 10/30/21 Due: 10/30/22

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05917509 Org: User:
Start: 07/28/23 End: 09/03/26 Due: 09/03/27

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

Phase: N/A Priority: Normal
NCT ID: NCT02738931 Org: User:
Start: 05/31/16 End: 06/30/16 Due: 06/30/17

A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01467531 Org: User:
Start: 11/30/11 End: 02/29/12 Due: 02/28/13

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

Phase: N/A Priority: Normal
NCT ID: NCT02831673 Org: User:
Start: 07/21/16 End: 08/15/22 Due: 08/15/23

Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

Phase: N/A Priority: Normal
NCT ID: NCT00643643 Org: User:
Start: 10/31/02 End: 06/30/03 Due: 06/30/04

A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

Phase: N/A Priority: Normal
NCT ID: NCT05631704 Org: User:
Start: 12/02/22 End: 08/31/23 Due: 08/31/24